Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
NCT02619669 · Gary Schwartz · PHASE1 · withdrawn · last registry update 2020-03-12 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was withdrawn, because no participants were enrolled in two years.” | – | Registry record, Gary Schwartz |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTOR in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-12-19Results posted on the registry: Calithera Biosciences, Inc, Fulvestrant + Sapanisertib (NCT02756364)
- 2020-12-08Also stopped (terminated): Novartis Pharmaceuticals, BEZ235 + Paclitaxel (NCT01495247)
- 2020-04-28Also stopped (withdrawn): Abramson Cancer Center at Penn Medicine, Hydroxychloroquine (HCQ) + Gedatolisib (NCT03400254)
- 2020-01-27Results posted on the registry: Calithera Biosciences, Inc, Sapanisertib + Fulvestrant (NCT02049957)
- 2019-03-25Results posted on the registry: Merck Sharp & Dohme LLC, Ridaforolimus + Dalotuzumab (NCT01605396)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision